Allogene Therapeutics Inc
ALLO
Get informed when a big investor buys or sells
+ FollowMarket Cap$721.37M
Close$
$-0.14
106.5% downside
Current Fair Value
106.5% downsideOvervalued by 106.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $721.37 Million |
|---|---|
| Enterprise Value | $753.10 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.87 |
| Beta | 0.47 |
| Outstanding Shares | 328,930,269 |
Return
| Return on Equity | -37.94% |
|---|---|
| Return on Assets | -30.08% |
| Return on Invested Capital | -36.91% |
Valuation & Multiples
| P/E Ratio | -3.12 |
|---|---|
| PEG | 19.22 |
| Price to Sales | - |
| Price to Book Ratio | 2.19 |
| Enterprise Value to Revenue | 162.31 |
| Enterprise Value to EBIT | -3.94 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$2,500
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$2,500
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5608▲ 11.70% |
|---|---|
| Total Calls | 295,100▲ 5.54% |
| Total Puts | 165,500▲ 33.36% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 131.07%▲ 54.41% |
|---|---|
| Total Invested | $660.38M▲ 48.49% |
| Investors Holding | 215▲ 1.00% |
ESG Score
No data